Jean-Luc Raoul

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/10687876/publications.pdf

Version: 2024-02-01

59 papers	35,689 citations	125106 35 h-index	150775 59 g-index
60 all docs	60 docs citations	60 times ranked	32727 citing authors

#	Article	IF	Citations
1	Loco-regional treatments of unresectable hepatocellular carcinoma: safety first. Hepatobiliary Surgery and Nutrition, 2022, 11, 324-326.	0.7	0
2	Case Report: Two Cases of Metastatic Pancreatoblastoma in Adults: Efficacy of Folfirinox and Implication of the Wnt/Î²-Catenin Pathway in Genomic Analysis. Frontiers in Oncology, 2021, 11, 564506.	1.3	6
3	Cost-Utility Analysis of Transarterial Radioembolization With Yttrium-90 Resin Microspheres Compared With Sorafenib in Locally Advanced and Inoperable Hepatocellular Carcinoma. Clinical Therapeutics, 2021, 43, 1201-1212.	1.1	4
4	Expected outcomes and patientsâ€™ selection before chemoembolizationâ€”â€œSix-and-Twelve or Pre-TACE-Predictâ€•scores may help clinicians: Real-life French cohorts results. World Journal of Clinical Cases, 2021, 9, 4559-4572.	0.3	4
5	Systemic treatment of hepatocellular carcinoma: standard of care in China and elsewhere. Lancet Oncology, The, 2020, 21, 479-481.	5.1	29
6	Current options and future possibilities for the systemic treatment of hepatocellular carcinoma. Hepatic Oncology, 2019, 6, HEP11.	4.2	24
7	Sorafenib: Experience and Better ManageÂment of Side Effects Improve Overall Survival in Hepatocellular Carcinoma Patients: A Real-Life Retrospective Analysis. Liver Cancer, 2019, 8, 457-467.	4.2	42
8	Hepatocellular carcinoma macroscopic gross appearance on imaging: predictor of outcome after transarterial chemoembolization in a real-life multicenter French cohort. European Journal of Gastroenterology and Hepatology, 2019, 31, 1414-1423.	0.8	4
9	Updated use of TACE for hepatocellular carcinoma treatment: How and when to use it based on clinical evidence. Cancer Treatment Reviews, 2019, 72, 28-36.	3.4	342
10	EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. Journal of Hepatology, 2018, 69, 182-236.	1.8	6,153
11	Potential of ramucirumab in treating hepatocellular carcinoma patients with elevated baseline alpha-fetoprotein. Journal of Hepatocellular Carcinoma, 2018, Volume 5, 91-98.	1.8	10
12	FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer. New England Journal of Medicine, 2018, 379, 2395-2406.	13.9	1,931
13	Systemic therapy for intermediate and advanced hepatocellular carcinoma: Sorafenib and beyond. Cancer Treatment Reviews, 2018, 68, 16-24.	3.4	124
14	Patients with resectable pancreatic adenocarcinoma: A 15-years single tertiary cancer center study of laparotomy findings, treatments and outcomes. Surgical Oncology, 2018, 27, 619-624.	0.8	2
15	Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC. Journal of Hepatology, 2017, 66, 1166-1172.	1.8	178
16	Systemic chemotherapy with FOLFOX in metastatic grade 1/2 neuroendocrine cancer. Molecular and Clinical Oncology, 2017, 6, 44-48.	0.4	22
17	Gene expression profiling of patientâ€derived pancreatic cancer xenografts predicts sensitivity to the <scp>BET</scp> bromodomain inhibitor <scp>JQ</scp> 1: implications for individualized medicine efforts. EMBO Molecular Medicine, 2017, 9, 482-497.	3.3	66
18	Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial. Lancet Oncology, The, 2017, 18, 1624-1636.	5.1	595

#	Article	IF	Citations
19	An in-depth review of chemical angiogenesis inhibitors for treating hepatocellular carcinoma. Expert Opinion on Pharmacotherapy, 2017, 18, 1467-1476.	0.9	23
20	An elevated serum alkaline phosphatase level in hepatic metastases of grade 1 and 2 gastrointestinal neuroendocrine tumors is unusual and of prognostic value. PLoS ONE, 2017, 12, e0177971.	1.1	7
21	Patient-Reported Outcomes and Quality of Life with Sunitinib Versus Placebo for Pancreatic Neuroendocrine Tumors: Results From an International Phase III Trial. Targeted Oncology, 2016, 11, 815-824.	1.7	45
22	Treatment of Pancreatic Adenocarcinoma in Elderly Patients over 75ÂYears of Age: A Retrospective Series of 129 Patients. Journal of Gastrointestinal Cancer, 2016, 47, 15-19.	0.6	10
23	Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. Lancet, The, 2016, 387, 545-557.	6.3	878
24	Heterogeneity of metastatic pancreatic adenocarcinoma: Lung metastasis show better prognosis than liver metastasisâ€"a case control study. Oncotarget, 2016, 7, 45649-45655.	0.8	26
25	How to assess the efficacy or failure of targeted therapy: Deciding when to stop sorafenib in hepatocellular carcinoma. World Journal of Hepatology, 2016, 8, 1541.	0.8	10
26	Yttrium-90 Microsphere Radioembolization for Hepatocellular Carcinoma. Liver Cancer, 2015, 4, 16-25.	4.2	40
27	Personalized Dosimetry with Intensification Using ⁹⁰Y-Loaded Glass Microsphere Radioembolization Induces Prolonged Overall Survival in Hepatocellular Carcinoma Patients with Portal Vein Thrombosis. Journal of Nuclear Medicine, 2015, 56, 339-346.	2.8	122
28	Intermediate-stage HCCâ€"upfront resection can be feasible. Nature Reviews Clinical Oncology, 2015, 12, 295-295.	12.5	7
29	Heterogeneity of intermediate-stage HCC necessitates personalized management including surgery. Nature Reviews Clinical Oncology, 2015, 12, 10-10.	12.5	20
30	Using Modified RECIST and Alpha-Fetoprotein Levels to Assess Treatment Benefit in Hepatocellular Carcinoma. Liver Cancer, 2014, 3, 439-450.	4.2	21
31	Treatment of intermediate-stage hepatocellular carcinoma. Nature Reviews Clinical Oncology, 2014, 11, 525-535.	12.5	377
32	High Prognostic Value of ¹⁸F-FDG PET for Metastatic Gastroenteropancreatic Neuroendocrine Tumors: A Long-Term Evaluation. Journal of Nuclear Medicine, 2014, 55, 1786-1790.	2.8	153
33	How to Define Transarterial Chemoembolization Failure or Refractoriness: A European Perspective. Liver Cancer, 2014, 3, 119-124.	4.2	118
34	Tivantinib in MET-high hepatocellular carcinoma patients and the ongoing Phase III clinical trial. Hepatic Oncology, 2014, 1, 181-188.	4.2	16
35	One case of intrahepatic cholangiocarcinoma amenable to resection after radioembolization. World Journal of Gastroenterology, 2014, 20, 5131.	1.4	14
36	Volumetric Changes after 90Y Radioembolization for Hepatocellular Carcinoma in Cirrhosis: An Option to Portal Vein Embolization in a Preoperative Setting?. Annals of Surgical Oncology, 2013, 20, 2518-2525.	0.7	76

#	Article	IF	Citations
37	Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study. Journal of Clinical Oncology, 2013, 31, 3517-3524.	0.8	675
38	Brivanib in Patients With Advanced Hepatocellular Carcinoma Who Were Intolerant to Sorafenib or for Whom Sorafenib Failed: Results From the Randomized Phase III BRISK-PS Study. Journal of Clinical Oncology, 2013, 31, 3509-3516.	0.8	544
39	Impact of FOLFIRINOX Compared With Gemcitabine on Quality of Life in Patients With Metastatic Pancreatic Cancer: Results From the PRODIGE 4/ACCORD 11 Randomized Trial. Journal of Clinical Oncology, 2013, 31, 23-29.	0.8	394
40	Multidisciplinary strategies to improve treatment outcomes in hepatocellular carcinoma. European Journal of Gastroenterology and Hepatology, 2013, 25, 639-651.	0.8	34
41	Role of the multidisciplinary team in the diagnosis and treatment of hepatocellular carcinoma. Expert Review of Gastroenterology and Hepatology, 2012, 6, 173-185.	1.4	57
42	Why is pancreatic cancer difficult to treat in the elderly?. Aging Health, 2012, 8, 301-307.	0.3	2
43	Relationship between baseline hepatic status and outcome, and effect of sorafenib on liver function: SHARP trial subanalyses. Journal of Hepatology, 2012, 56, 1080-1088.	1.8	109
44	Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial. Journal of Hepatology, 2012, 57, 821-829.	1.8	736
45	Dosimetry Based on ^{99m}Tc-Macroaggregated Albumin SPECT/CT Accurately Predicts Tumor Response and Survival in Hepatocellular Carcinoma Patients Treated with ⁹⁰Y-Loaded Glass Microspheres: Preliminary Results. Journal of Nuclear Medicine, 2012, 53, 255-263.	2.8	242
46	Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma. Cancer, 2012, 118, 147-156.	2.0	250
47	FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer. New England Journal of Medicine, 2011, 364, 1817-1825.	13.9	6,140
48	Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors. New England Journal of Medicine, 2011, 364, 501-513.	13.9	2,216
49	Impressive efficacy of sorafenib in a patient with an hepatocellular carcinoma and a portal vein thrombosis associated with a metastatic ENT cancer. Medical Oncology, 2011, 28, 246-249.	1.2	1
50	Adjuvant gemcitabine versus NEOadjuvant gemcitabine/oxaliplatin plus adjuvant gemcitabine in resectable pancreatic cancer: a randomized multicenter phase III study (NEOPAC study). BMC Cancer, 2011, 11, 346.	1.1	93
51	Phase II, Open-Label Study of Brivanib as First-Line Therapy in Patients with Advanced Hepatocellular Carcinoma. Clinical Cancer Research, 2011, 17, 1973-1983.	3.2	142
52	First experience of hepatic radioembolization using microspheres labelled with yttrium-90 (TheraSphere): practical aspects concerning its implementation. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 453-461.	3.3	38
53	Treatment of hepatocellular carcinoma with intra-arterial injection of radionuclides. Nature Reviews Gastroenterology and Hepatology, 2010, 7, 41-49.	8.2	47
54	Increased Lipiodol uptake in hepatocellular carcinoma possibly due to increased membrane fluidity by dexamethasone and tamoxifen. Nuclear Medicine and Biology, 2010, 37, 777-784.	0.3	14

#	Article	IF	Citations
55	Predictive Value of ¹⁸F-FDG PET and Somatostatin Receptor Scintigraphy in Patients with Metastatic Endocrine Tumors. Journal of Nuclear Medicine, 2009, 50, 858-864.	2.8	224
56	Treatment of advanced hepatocellular carcinoma with long-acting octreotide: A phase III multicentre, randomised, double blind placebo-controlled study. European Journal of Cancer, 2009, 45, 1788-1797.	1.3	59
57	Systemic chemotherapy for hepatocellular carcinoma in non-cirrhotic liver: A retrospective study. World Journal of Gastroenterology, 2009, 15, 713.	1.4	40
58	Sorafenib in Advanced Hepatocellular Carcinoma. New England Journal of Medicine, 2008, 359, 378-390.	13.9	12,004
59	Randomized Controlled Trial of Tamoxifen in Advanced Hepatocellular Carcinoma. Journal of Clinical Oncology, 2005, 23, 4338-4346.	0.8	127